Weighted Average Number of Shares Outstanding, Basic of CRISPR Therapeutics AG from 31 Mar 2016 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
CRISPR Therapeutics AG quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 31 Mar 2016 to 31 Dec 2025.
  • CRISPR Therapeutics AG Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 89,925,109, a 6.6% increase year-over-year.
  • CRISPR Therapeutics AG annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 89,925,109, a 6.6% increase from 2024.
  • CRISPR Therapeutics AG annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 84,359,126, a 6.5% increase from 2023.
  • CRISPR Therapeutics AG annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 79,220,930, a 1.9% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

CRISPR Therapeutics AG Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 89,925,109 +5,565,983 +6.6% 01 Oct 2025 31 Dec 2025 10-K 12 Feb 2026 2025 FY
Q3 2025 91,305,337 +6,070,411 +7.1% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 87,069,690 +2,148,761 +2.5% 01 Apr 2025 30 Jun 2025 10-Q 04 Aug 2025 2025 Q2
Q1 2025 85,938,720 +4,144,090 +5.1% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 84,359,126 +5,138,196 +6.5% 01 Oct 2024 31 Dec 2024 10-K 12 Feb 2026 2025 FY
Q3 2024 85,234,926 +5,820,828 +7.3% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 84,920,929 +5,829,868 +7.4% 01 Apr 2024 30 Jun 2024 10-Q 04 Aug 2025 2025 Q2
Q1 2024 81,794,630 +3,117,644 +4% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 79,220,930 +1,474,355 +1.9% 01 Oct 2023 31 Dec 2023 10-K 12 Feb 2026 2025 FY
Q3 2023 79,414,098 +1,392,578 +1.8% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 79,091,061 +1,577,734 +2% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 78,676,986 +1,578,667 +2% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 77,746,575 +1,797,889 +2.4% 01 Oct 2022 31 Dec 2022 10-K 11 Feb 2025 2024 FY
Q3 2022 78,021,520 +1,732,986 +2.3% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 77,513,327 +1,686,733 +2.2% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 77,098,319 +2,093,132 +2.8% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 75,948,686 +4,666,590 +6.5% 01 Oct 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
Q3 2021 76,288,534 +6,145,053 +8.8% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022 2022 Q3
Q2 2021 75,826,594 +14,405,848 +23% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 75,005,187 +14,157,504 +23% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 71,282,096 +13,886,257 +24% 01 Oct 2020 31 Dec 2020 10-K 16 Feb 2021 2020 FY
Q3 2020 70,143,481 +15,314,424 +28% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 61,420,746 +8,232,705 +15% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021 2021 Q2
Q1 2020 60,847,683 +8,754,475 +17% 01 Jan 2020 31 Mar 2020 10-Q 27 Apr 2021 2021 Q1
Q4 2019 57,395,839 +5,707,456 +11% 01 Oct 2019 31 Dec 2019 10-K 16 Feb 2021 2020 FY
Q3 2019 54,829,057 +7,437,069 +16% 01 Jul 2019 30 Sep 2019 10-K 16 Feb 2021 2020 FY
Q2 2019 53,188,041 +6,345,725 +14% 01 Apr 2019 30 Jun 2019 10-K 16 Feb 2021 2020 FY
Q1 2019 52,093,208 +6,215,780 +14% 01 Jan 2019 31 Mar 2019 10-K 16 Feb 2021 2020 FY
Q4 2018 51,688,383 +11,178,486 +28% 01 Oct 2018 31 Dec 2018 10-K 12 Feb 2020 2019 FY
Q3 2018 47,391,988 +7,303,270 +18% 01 Jul 2018 30 Sep 2018 10-K 12 Feb 2020 2019 FY
Q2 2018 46,842,316 +6,946,378 +17% 01 Apr 2018 30 Jun 2018 10-K 12 Feb 2020 2019 FY
Q1 2018 45,877,428 +6,151,481 +15% 01 Jan 2018 31 Mar 2018 10-K 12 Feb 2020 2019 FY
Q4 2017 40,509,897 +7,522,562 +23% 01 Oct 2017 31 Dec 2017 10-K 25 Feb 2019 2018 FY
Q3 2017 40,088,718 +34,796,370 +657% 01 Jul 2017 30 Sep 2017 10-K 25 Feb 2019 2018 FY
Q2 2017 39,895,938 +34,447,083 +632% 01 Apr 2017 30 Jun 2017 10-K 25 Feb 2019 2018 FY
Q1 2017 39,725,947 +34,197,868 +619% 01 Jan 2017 31 Mar 2017 10-K 25 Feb 2019 2018 FY
Q4 2016 32,987,335 01 Oct 2016 31 Dec 2016 10-K 08 Mar 2018 2017 FY
Q3 2016 5,292,348 01 Jul 2016 30 Sep 2016 10-K 08 Mar 2018 2017 FY
Q2 2016 5,448,855 01 Apr 2016 30 Jun 2016 10-K 08 Mar 2018 2017 FY
Q1 2016 5,528,079 01 Jan 2016 31 Mar 2016 10-K 08 Mar 2018 2017 FY

CRISPR Therapeutics AG Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 89,925,109 +5,565,983 +6.6% 01 Jan 2025 31 Dec 2025 10-K 12 Feb 2026 2025 FY
2024 84,359,126 +5,138,196 +6.5% 01 Jan 2024 31 Dec 2024 10-K 12 Feb 2026 2025 FY
2023 79,220,930 +1,474,355 +1.9% 01 Jan 2023 31 Dec 2023 10-K 12 Feb 2026 2025 FY
2022 77,746,575 +1,797,889 +2.4% 01 Jan 2022 31 Dec 2022 10-K 11 Feb 2025 2024 FY
2021 75,948,686 +9,999,014 +15% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
2020 65,949,672 +11,557,368 +21% 01 Jan 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
2019 54,392,304 +6,427,936 +13% 01 Jan 2019 31 Dec 2019 10-K 15 Feb 2022 2021 FY
2018 47,964,368 +7,907,003 +20% 01 Jan 2018 31 Dec 2018 10-K 16 Feb 2021 2020 FY
2017 40,057,365 01 Jan 2017 31 Dec 2017 10-K 12 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.